Enlivex Therapeutics Ltd (ENLV)

May 20, 2025, 8:00 AM EDT - 17 days ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Apr 23, 2025, 8:30 AM EDT - 6 weeks ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Apr 21, 2025, 8:30 AM EDT - 6 weeks ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Apr 3, 2025, 8:00 AM EDT - 2 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Mar 17, 2025, 8:00 AM EDT - 2 months ago

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Mar 4, 2025, 4:30 PM EST - 3 months ago

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Mar 3, 2025, 8:22 AM EST - 3 months ago

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Feb 18, 2025, 6:20 AM EST - 3 months ago

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Jan 10, 2025, 9:00 AM EST - 5 months ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Dec 11, 2024, 8:30 AM EST - 6 months ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 6 months ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nov 26, 2024, 10:15 AM EST - 6 months ago

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Nov 14, 2024, 8:00 AM EST - 7 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Oct 30, 2024, 8:00 AM EDT - 7 months ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Sep 24, 2024, 8:30 AM EDT - 9 months ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Aug 30, 2024, 9:00 AM EDT - 10 months ago

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GP

Jul 19, 2024, 9:00 AM EDT - 11 months ago

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

May 29, 2024, 4:15 PM EDT - 1 year ago

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

May 28, 2024, 8:12 AM EDT - 1 year ago

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Apr 16, 2024, 7:50 AM EDT - 1 year ago

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Apr 11, 2024, 2:58 PM EDT - 1 year ago

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Apr 11, 2024, 8:05 AM EDT - 1 year ago

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Mar 22, 2024, 10:50 AM EDT - 1 year ago

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

UMAC

Feb 26, 2024, 8:30 AM EST - 1 year ago

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Feb 21, 2024, 8:30 AM EST - 1 year ago

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Jan 17, 2024, 8:00 AM EST - 1 year ago

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Dec 20, 2023, 8:00 AM EST - 1 year ago

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Jul 31, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Enlivex to Present at the 2023 Jefferies Healthcare Conference

May 31, 2023, 8:04 AM EDT - 2 years ago

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

May 8, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

Apr 19, 2023, 8:00 AM EDT - 2 years ago

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Apr 17, 2023, 8:00 AM EDT - 2 years ago

Enlivex Appoints Andrew Singer to its Board of Directors

Apr 14, 2023, 9:40 AM EDT - 2 years ago

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Apr 12, 2023, 10:45 AM EDT - 2 years ago

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

Apr 3, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

Mar 20, 2023, 8:00 AM EDT - 2 years ago

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

Feb 15, 2023, 8:00 AM EST - 2 years ago

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Jan 25, 2023, 8:37 AM EST - 2 years ago

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Dec 5, 2022, 8:00 AM EST - 2 years ago

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

Nov 15, 2022, 8:00 AM EST - 2 years ago

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Oct 3, 2022, 8:13 AM EDT - 2 years ago

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

Sep 30, 2022, 2:08 AM EDT - 2 years ago

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Sep 13, 2022, 8:00 AM EDT - 2 years ago

Enlivex to Present at Upcoming Investor and Media Conferences

Sep 12, 2022, 8:00 AM EDT - 2 years ago

Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Aug 29, 2022, 8:00 AM EDT - 3 years ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells

Aug 24, 2022, 8:00 AM EDT - 3 years ago

Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Aug 22, 2022, 8:00 AM EDT - 3 years ago

Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update